New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
10:49 EDTSRPT, INFY, GOOG, NSR, CMGOptions with decreasing implied volatility: SRPT NSR INFY CMG GOOG
News For SRPT;NSR;INFY;CMG;GOOG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
November 20, 2015
09:19 EDTSRPTSarepta competitive advantage being read into Biomarin docs, says Piper Jaffray
Subscribe for More Information
08:05 EDTSRPTBioMarin drops after FDA posts review of DMD drug drisapersen
Shares of BioMarin are down 7% to $96.01 after the FDA posted a review of the company's Duchenne muscular dystrophy treatment drisapersen ahead of Tuesday's panel vote. Sarepta Therapeutics (SRPT), which is developing its own treatment for DMD, is trading higher while PTC Therapeutics (PTCT) is moving lower. Reference Link
November 19, 2015
16:11 EDTGOOGGoogle names VMware co-founder to lead cloud businesses
Subscribe for More Information
14:49 EDTSRPTBefore the Move: Watch BioMarin into FDA advisory committee
BioMarin Pharmaceutical (BMRN), which develops and commercializes pharmaceuticals for serious diseases and medical conditions including Duchenne muscular dystrophy, or DMD, is awaiting an FDA advisory committee for its DMD drug drisapersen, which is brand named Kyndrisa. WHAT'S NEW: The Peripheral and Central Nervous System Drugs Advisory Committee is meeting on Tuesday, November 24 to discuss the New Drug Application, or NDA, for Biomarin's drisapersen. It is expected that briefing documents related to that meeting will be posted on the FDA's website tomorrow, Friday, November 20. BULLISH TAKE: On November 15, Leerink analyst Joseph Schwartz said he believes the FDA will feel compelled to approve at least one DMD drug due to "public attention and vocal demand," and says that most likely both drisapersen and Sarepta Therapeutics' (SRPT) eteplirsen will be approved. However, he also makes a case where eteplirsen is not approved due to the "extremely limited" clinical data on the drug. Schwartz noted that drisapersen's advisory panel on November 24 happens first and will be important for both companies, adding that he sees "significant" upside potential for BioMarin. On November 18, Goldman Sachs said it views the risk/reward in BioMarin as favorable, with the advisory committee as a key catalyst on the company's path to non-GAAP profitability. Goldman has a Buy rating on BioMarin shares. On November 19, Jefferies analyst Gena Wang wrote that a buy-side survey the firm conducted suggests positive expectations for BioMarin's advisory committee. Wang, who said the survey of 58 investors suggests buy-side expectations of a positive panel for Kyndrisa are 62%, noted that a positive outcome could push BioMarin higher by almost 20%, and positively impact peers PTC Therapeutics (PTCT) and Sarepta by over 20% and 6%, respectively. BAIRD CAUTIOUS: On November 19, Baird analyst Brian Skorney wrote a note titled "A Skeptic's Guide to DMD Regulatory Reviews" where he says the firm has "increasingly come to believe that the FDA is more likely to reject the NDA's for drisapersen and eteplirsen," although he notes the risk reward for BioMarin is skewed to the upside -- with 20% upside potential on approval, but only 10% downside potential on rejection. Baird has a Neutral rating on BioMarin. Skorney sees a 30% probability both drugs get approved during this review period, a 5% chance BioMarin's drug gets approved and Sarepta's gets rejected, a 5% chance Sarepta's gets approved and BioMarin's gets rejected, and a 60% chance that both get rejected. PRICE ACTION: In afternoon trading on Thursday, shares of BioMarin were down about 4.5% to $102.88, while shares of peers Sarepta and PTC Therapeutics were down 8% and 9.5%, respectively.
09:46 EDTGOOGYouTube to pay legal fees for some video makers to fight battles, NY Times says
YouTube said it will begin to financial support YouTube creators fight back battles over copyright infringement, reports the New York Times. It said will pick up the legal costs of a handful of video creators that the company thinks are the targets of unfair takedowns. Reference Link
08:28 EDTSRPTBaird sees 60% chance BioMarin, Sarepta DMD drugs both get rejected
Baird analyst Brian Skorney said he increasingly thinks that the FDA is more likely to reject the NDA's for the two Duchenne muscular dystrophy drugs it will soon review, BioMarin's (BMRN) drisapersen and Sarepta's (SRPT) eteplirsen, though he notes that his confidence in any of the various approval/rejection scenarios is low. Skorney sees a 30% probability both drugs get approved during this review period, a 5% chance BioMarin's drug gets approved and Sarepta's gets rejected, a 5% chance Sarepta's gets approved and BioMarin's gets rejected, and a 60% chance that both get rejected. Skorney, who sees 20% upside potential and 10% downside potential for Biomarin based on this event, keeps a Neutral rating on its shares. The analyst thinks the risk-reward for Sarepta, however, is "massively" skewed to the upside, with 250% upside potential compared to 50% downside, and keeps an Outperform rating on its shares.
07:55 EDTGOOGGM's Reuss: Company 'deeply committed' to EVs, FT says
Subscribe for More Information
07:23 EDTSRPTBuy-side sees 62% chance of positive BioMarin panel, says Jefferies
Jefferies analyst Gena Wang says her firm's survey of 58 investors suggests buy-side expectations of a positive FDA panel on November 24 for BioMarin's (BMRN) Kyndrisa are 62%. Both positive and negative outcomes are expected to result in significant moves for all three stocks developing treatments for Duchenne muscular dystrophy, or BioMarin, Sarepta (SRPT) and PTC Therapeutics (PTCT), Wang tells investors in a research note. Investors expect a positive Kyndrisa outcome to push BioMarin shares 19% higher, PTC shares 23% higher and Sarepta shares 6% higher, the analyst points out. She notes that a negative panel vote is expected to drive all three stocks 20%-30% lower.
06:32 EDTGOOGAkamai announces collaboration with Google Cloud Platform
Subscribe for More Information
06:26 EDTGOOGGoogle's Hoelzle: Cloud could generate more revenue than ads by 2020, BI says
Subscribe for More Information
November 18, 2015
16:44 EDTGOOGGoogle ad exec jumps to YouTube, Re/code says
Neal Mohan, previously Google's (GOOG) SVP for display and video advertising, has been appointed SVP of product for YouTube in a move signaling renewed efforts to combat Facebook (FB) video, reports Re/code, citing spokesperson statements. Paul Muret, currently head of analytics at Google, will succeed Mohan, and the company's analytics group will be folded into its display operations. Re/code notes that the analytics rollup may indicate Google sees measurement as "core" to its advertising business. Reference Link
11:24 EDTGOOGGoogle eyes YouTube enhancement with VR experiences, DigiTimes says
Subscribe for More Information
November 17, 2015
19:11 EDTGOOGGoogle launches redesigned Google+
Subscribe for More Information
11:25 EDTGOOGGoogle to fight Russia's antitrust ruling on Android platform, Reuters reports
Subscribe for More Information
08:44 EDTSRPTSarepta says eteplirsen study shows 'positive' results
Subscribe for More Information
06:35 EDTGOOGGoogle's Project Aura working on three new wearables, the Information says
Google's revamped Google Glass project, known as Project Aura, is developing a wearable with a screen and at least one without, the Information reports. Three versions of the head-mounted device are currently in development, though three may be consolidated into two, the report says. The two without a screen rely on bone conduction, much like the original Google Glass, the report says. Reference Link
November 16, 2015
09:33 EDTGOOGeBay second week of November SSS up 0.4%, ChannelAdvisor says
Subscribe for More Information
08:28 EDTCMGChipotle comps likely to fall in Q4, 1Q16, says Bernstein
Subscribe for More Information
07:16 EDTSRPTFDA likely feels compelled to approve at least one DMD drug, says Leerink
Leerink analyst Joseph Schwartz says the FDA likely feels compelled to approve at least one of the exon skipping drugs to treat Duchenne muscular dystrophy in this review cycle. There is so much public attention and vocal demand in the DMD community, Schwartz tells investors in a research note. The FDA advisory panel on BioMarin's (BMRN) drisapersen is on November 24 while the panel on Sarepta's (SRPT) eteplirsen is tentatively scheduled for January 22, 2016. The greatest likelihood is that both drugs are approved, Schwartz contends. Shares of BioMarin have "significant" upside potential on a positive panel vote as many investors still doubt that drisapersen is approvable based on existing data, and approval would "greatly aid" the company's goal to reach profitability, the analyst argues. He reiterates an Outperform rating on BioMarin and a Market Perform rating on Sarepta. Jefferies analyst Eun Yang said on Friday that regulatory experts she spoke with see a high likelihood of a positive FDA panel vote BioMarin.
06:27 EDTGOOGYandex extends Google antitrust battle to EU, Bloomberg reports
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use